This phase III trial is evaluating the combination of an immunotherapy drug (pembrolizumab) and platinum-based doublet chemotherapy, with or without an additional therapy (canakinumab), in patients with advanced or metastatic non-small cell lung cancer.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects
This is a randomised trial, in which patients will receive pembrolizumab and platinum-based doublet chemotherapy (containing carboplatin, cisplatin, paclitaxel, nab-paclitaxel and pemetrexed) with or without canakinumab.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More